1 Min Read
May 15 (Reuters) - Nuvo Pharmaceuticals Inc
* Nuvo Pharmaceuticals Inc announces topline results from European ankle sprain study with Pennsaid 2 pct
* Nuvo Pharmaceuticals Inc - trial had failed to meet its primary endpoint
* Nuvo Pharmaceuticals - will continue to assess opportunities available to pursue marketing authorizations for Pennsaid 2 pct in Canada, Australia and E.U.
* Nuvo Pharmaceuticals - will be reviewing trial results in with its scientific advisors and regulatory consultants to determine what its next steps should be Source text for Eikon: Further company coverage: